Endocrine Oncology

Development of specific diagnostic and therapeutic modalities for endocrine tumors have been developed by the Department of Endocrine Oncology and the Endocrine Surgery.
They pioneered specific cytotoxic treatment (streptozotocin + 5FU), therapy with somatostatin analogs and alpha interferons. A more active surgery including wide resections, debulking, radiofrequency ablation was developed at the Department of Endocrine Surgery. Specific biochemical markers, tachykinins and chromogranin A became new diagnostic tools and unique PET-scannings were developed including C11-5HTP, Ga68 PET.

National referral center
Today more than 2500 patients with different forms of neuroendocrine tumors have been managed. The Department of Endocrine Oncology was appointed National referral center for endocrine tumors in 1986 in Sweden. About 20 per cent of current patient referrals are coming from Europe, the United States, South America and Asia. The international
referrals have steadily increased and the center is now considered unique of its kind in the world. The center has been involved in establishing Scandinavian, European and North American Networks for patients with neuroendocrine tumors (GETNE, ENETS, NANETS). Furthermore, a European patient’s network for patients with neuroendocrine tumors was established at this center (CARPA).

As a result of dedicated treatment of patients with endocrine tumors the survival is significantly better than can be offered as standard of care in many places in other parts of the world.